Madrigal Pharmaceuticals (MDGL) Stock Forecast & Price Target

Madrigal Pharmaceuticals is viewed favorably because Rezdiffra is the first approved MASH therapy and early launch metrics, physician preference, and safety-profile feedback suggest strong demand in a large, underpenetrated market with roughly 10-20M patients in the US alone. The thesis is further supported by upward revisions to 2036 peak US patients treated with Rezdiffra to 193k from 158k, total WW peak adjusted revenue to $8.9B from $7.7B, and a longer exclusivity window than the Street models imply. In addition, the $25M upfront Arrowhead license for ARO-PNPLA3, with up to $975M in milestones plus royalties and up to 46% liver fat reduction in I148M homozygotes, expands Madrigal into a combination-platform franchise and could create incremental value beyond Rezdiffra.

Madrigal Pharmaceuticals is vulnerable to multiple fundamental risks that could undermine the long-term thesis despite Rezdiffra’s promise in MASH, including the possibility of FDA and EMA approval setbacks, weak or equivocal Outcomes study data, and delays that would slow commercial scaling. The valuation framework itself appears highly dependent on future execution, with nearly all modeled value tied to Rezdiffra in moderate-to-advanced fibrosis and compensated cirrhosis, while zero terminal value is assigned beyond 2033, leaving little margin for disappointment. Even with projected peak sales of nearly $9.4B in 2033 for fibrotic MASH and about $1B in cirrhotic MASH, the company still faces competitive threats and the risk of needing to fund operations on unfavorable terms.